» Articles » PMID: 29370457

Development of a Novel Tc-labeled Small Molecular Antagonist for CXCR4 Positive Tumor Imaging

Overview
Date 2018 Jan 26
PMID 29370457
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

The chemokine receptor 4 (CXCR4) has been an attractive molecular target for tumor imaging, because it is overexpressed in many tumor types and involved in tumor progression and metastasis. The purpose of this study is to examine the CXCR4 targeting properties of Tc-labeled AMD3465, a small molecule antagonist of CXCR4. Tc-AMD3465 was prepared in high yield (>95%) and stable in mice serum at least for 4 hours. In vitro cell binding experiments were performed with Chinese hamster ovary (CHO), MCF-7 (breast cancer), and CHO-CXCR4 (CHO stably transfected to express CXCR4) cell lines. Small animal single photon emission computed tomography/computed tomography imaging studies in nude mice bearing MCF-7 and CHO xenografts showed that the uptakes of the radiotracer in MCF-7 tumors were significantly higher than those in the CXCR4-negative CHO tumors (P < 0.05), and the MCF-7 tumors uptake could be blocked with an excess of unlabeled AMD3465 (P < 0.05). These results suggested that Tc-AMD3465 could be a potential single photon emission computed tomography radiotracer for CXCR4 imaging.

Citing Articles

Fabrication of Nanocrystals for Enhanced Distribution of a Fatty Acid Synthase Inhibitor (Orlistat) as a Promising Method to Relieve Solid Ehrlich Carcinoma-Induced Hepatic Damage in Mice.

Alamoudi J, El-Masry T, Nasr M, Ibrahim I, Ibrahim H, Saad H Pharmaceuticals (Basel). 2024; 17(1).

PMID: 38256929 PMC: 10820129. DOI: 10.3390/ph17010096.


[Tc]Tc-PentixaTec: development, extensive pre-clinical evaluation, and first human experience.

Konrad M, Rinscheid A, Wienand G, Nittbaur B, Wester H, Janzen T Eur J Nucl Med Mol Imaging. 2023; 50(13):3937-3948.

PMID: 37597009 PMC: 10611619. DOI: 10.1007/s00259-023-06395-x.


CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors.

Yu J, Zhou X, Shen L Molecules. 2023; 28(12).

PMID: 37375261 PMC: 10304366. DOI: 10.3390/molecules28124707.


In Vivo Targeting of CXCR4-New Horizons.

Schottelius M, Herrmann K, Lapa C Cancers (Basel). 2021; 13(23).

PMID: 34885030 PMC: 8656854. DOI: 10.3390/cancers13235920.


Preclinical Advances in Theranostics for the Different Molecular Subtypes of Breast Cancer.

Fang H, Cavaliere A, Li Z, Huang Y, Marquez-Nostra B Front Pharmacol. 2021; 12:627693.

PMID: 33986665 PMC: 8111013. DOI: 10.3389/fphar.2021.627693.